GLP-1s, a class of drugs used to treat type 2 diabetes, obesity, cardiovascular disease, and other conditions, have exploded in popularity in recent years due to their demonstrated effectiveness, but are often not covered by insurance, particularly for the treatment of obesity
Fat tissue is a source of an enzyme that can convert testosterone to estrogen, which protects your skeleton, Kohrt said
In November 2025, the Trump Administration announced an upcoming demonstration project that will extend coverage for GLP-1s to people living with obesity and related complications starting later in 2026
Understanding Collagen Synthesis and Cellular Repair Mechanisms GHK-Cu plays a crucial role in stimulating collagen production pathways through multiple mechanisms
Is NMN better absorbed than NAD